Mabpharm

Manufacturing · China · 51-200 Employees

View Company Info for Free

Overview

Headquarters

Libing Road Zhangjiang Hi-tech Park No 3...

Revenue

$43 Million

Industry

Manufacturing Pharmaceuticals Business Services Research & Development
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1

About Mabpharm

Mabpharm is a biopharmaceutical company in China, specializing in the development and production of new drugs and biosimilars for the treatment of cancer and autoimmune diseases.They are committed to bringing high-quality and affordable innovative biopharmaceuticals to the market through their highly efficient R&D systems and low-cost pharmaceutical production capabilities, and to leverage their extensive R&D experience to develop a wide range of therapeutic products. Their Taizhou Pharmaceutical production base has two buildings, each covering 15,000 square meters, and is housed in their single antibody production facility. Currently, their drug candidate pipeline currently includes 9 monoclonal antibody drugs, 3 of which are core products in Phase III clinical trials: CMAB007 (Omazumab), CMAB009 (Cetuximab) and CMAB008 (Inflix Infliximab). In addition, their other two drug candidates, CMAB809 (trastuzumab) and CMAB819 (navumab), have been approved for clinical trials.Explore more
Mabpharm's Social MediaPopular SearchesMabpharm LtdMabpharm上海晟珩生物技术有限公司SIC Code 28,283NAICS Code 32,325Show more

Mabpharm Org Chart

HW
China flag for contact location.

Chief Executive Officer

PhoneEmail
JL
China flag for contact location.

Vice President

PhoneEmail

PhoneEmail
Get the full picture
Sign in to uncover key details.
LZ
China flag for contact location.

Project Manager

PhoneEmail

PhoneEmail
Get the full picture
Sign in to uncover key details.

Is Mabpharm your ideal customer?

Let us give you the heads up on whether it's a good time to reach out

Recommended Actions

Illustration of an envelope

Company Profile Activity

i

Among all Manufacturing companies

Low Activity

High Activity

Activity Insights

Mabpharm is experiencing very low activity levels compared to other companies in the Manufacturing sector.

What does this means?

Mabpharm is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Mabpharm.

Mabpharm Tech Stack

Mabpharm News & Media

  • Simcere Zaiming Announce Approval of Cetuximab Beta in China by the NMPA

    NANJING, China, June 26, 2024 /PRNewswire/ -- On June 25, 2024, Simcere Zaiming, an innovative oncology company and a subsidiary of Simcere Pharmaceutical Group (2096.HK), announced that Enlituo® (generic name: cetuximab beta injection), a new generation anti-epidermal growth factor receptor (EGFR) antibody drug developed in collaboration with Mabpharm Limited (2181.HK), has recently received approval from the China National Medical Administration (NMPA) for marketing. Enlituo® is indicated for
Read more news

Top Manufacturing Companies

Frequently Asked Questions Regarding Mabpharm

What is Mabpharm's official website?
Mabpharm's official website is www.mabpharm.cn
What is Mabpharm's Revenue?
Mabpharm's revenue is $43 Million
What is Mabpharm's SIC code?
Mabpharm's SIC: 28,283
What is Mabpharm's NAICS code?
Mabpharm's NAICS: 32,325
How many employees does Mabpharm have?
Mabpharm has 51-200 employees
What industry does Mabpharm belong to?
Mabpharm is in the industry of: Manufacturing, Pharmaceuticals, Business Services
What technology does Mabpharm use?
Some of the popular technologies that Mabpharm uses are: Cloudflare CDN, Matomo, Font Awesome, Apache HTTP Server
What does Mabpharm do?

Mabpharm is a biopharmaceutical company in China, specializing in the development and production of new drugs and biosimilars for the treatment of cancer and autoimmune diseases.They are committed to bringing high-quality and affordable innovative biopharmaceuticals to the market through their highly efficient R&D systems and low-cost pharmaceutica... l production capabilities, and to leverage their extensive R&D experience to develop a wide range of therapeutic products. Their Taizhou Pharmaceutical production base has two buildings, each covering 15,000 square meters, and is housed in their single antibody production facility. Currently, their drug candidate pipeline currently includes 9 monoclonal antibody drugs, 3 of which are core products in Phase III clinical trials: CMAB007 (Omazumab), CMAB009 (Cetuximab) and CMAB008 (Inflix Infliximab). In addition, their other two drug candidates, CMAB809 (trastuzumab) and CMAB819 (navumab), have been approved for clinical trials.Read More

What are Mabpharm social media links?
Mabpharm Linkedin page
Is Mabpharm a public company?
Mabpharm is private company therefore does not currently have an official ticker symbol
See more information about Mabpharm

Get Started with ZoomInfo

Register for free

Sign Up for Free

Get started for free! No credit card needed. Enjoy up to 25 free contacts each month at no cost.
Elevate your prospecting to the next level

Supercharge Your Prospecting

Search ZoomInfo's database of 106M+ companies and 140M+ professionals to find your next lead.
Expand your business

Grow Your Business

Reveal both personal and business contact details, including emails and phone numbers, and close your most valuable buyers.